Langsjoen P H, Langsjoen P H, Folkers K
Department of Medicine, Scott & White Clinic, Temple, TX.
Int J Tissue React. 1990;12(3):169-71.
One hundred and forty-three cases of chronic, stable, non-secondary, non-hypertrophic cardiomyopathy, 98% of whom were in NYHA Classes III and IV, were given 100 mg of coenzyme Q10 orally in addition to their conventional medical programme in an open-label long-term study. Blood CoQ10 levels, clinical status, myocardial function and survival have been recorded now for almost 6 years. Mean control/CoQ10 levels of 0.85 micrograms/ml rose to 2 micrograms/ml in 3 months and remained stable at that level. Mean ejection fraction of 44% measured by systolic time interval analysis rose to 60% within 6 months and stabilized at that level with 84% of patients showing statistically significant improvement. Eighty-five percent of patients improved by one or two NYHA Classes. Survival figures were encouraging with an 11.1% mortality in 12 months and 17.8% mortality in 24 months, comparing favourably with several reports in the literature. There was no positive evidence of toxicity or intolerance in a total of 368.9 patient-years of exposure. Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy.
在一项开放标签的长期研究中，143例慢性、稳定、非继发性、非肥厚性心肌病患者（其中98%为纽约心脏协会心功能Ⅲ级和Ⅳ级），在接受常规治疗方案的基础上，口服100毫克辅酶Q10。目前已记录了近6年的血辅酶Q10水平、临床状况、心肌功能和生存率。通过收缩期时间间期分析测得的平均射血分数从44%在6个月内升至60%，并稳定在该水平，84%的患者有统计学意义的改善。85%的患者心功能改善一或两级。生存率数据令人鼓舞，12个月死亡率为11.1%，24个月死亡率为17.8%，与文献中的几份报告相比具有优势。在总共368.9患者年的暴露中，没有毒性或不耐受的阳性证据。辅酶Q10是慢性心肌病安全有效的长期治疗方法。
